S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

QNCX Quince Therapeutics Inc

1.6962

-0.0238 (-1.38%)

Last Updated: 13:01:20

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Quince Therapeutics Charts.

Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Quince Therapeutics Charts.

Quince Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 8 January 2025 (1 week ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 8 January 2025 (1 week ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 8 January 2025 (1 week ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Friday 27 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Thursday 26 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Wednesday 18 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form SC 13D - General Statement of Acquisition of Beneficial Ownership
Wednesday 13 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 13 November 2024 (2 months ago) • Edgar (US Regulatory)

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Wednesday 13 November 2024 (2 months ago) • Business Wire

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Tuesday 12 November 2024 (2 months ago) • Business Wire

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Monday 11 November 2024 (2 months ago) • Business Wire

More Quince Therapeutics Inc News Articles

Vontobel Financial Produ...

International Bank for R...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions